Evidenced Based Practice (EVP): GRADE Approach to Evidenced Based Guideline D...Michael Changaris
This slide show explores how to review literature and develop an understanding of the quality of the clinical evidence for a treatment modality. Reviews the development of a guideline based on evidence based GRADE process.
Learning objectives:
Recognize that many of the questions you receive will come from patients that just read an article on a news site or social media
Understand that the vast majority of them qualify as B.S. (bad science) rather than G.S. (good science)
Know how to evaluate the article to determine which category applies quickly
An introduction to the rationale and the two types (Write-in and Select-Menu) of Key Feature Questions. This presentation is based on an original article by Page and Bordage (1995).
Evidenced Based Practice (EVP): GRADE Approach to Evidenced Based Guideline D...Michael Changaris
This slide show explores how to review literature and develop an understanding of the quality of the clinical evidence for a treatment modality. Reviews the development of a guideline based on evidence based GRADE process.
Learning objectives:
Recognize that many of the questions you receive will come from patients that just read an article on a news site or social media
Understand that the vast majority of them qualify as B.S. (bad science) rather than G.S. (good science)
Know how to evaluate the article to determine which category applies quickly
An introduction to the rationale and the two types (Write-in and Select-Menu) of Key Feature Questions. This presentation is based on an original article by Page and Bordage (1995).
This topic is very essential for Pharm.D students. It includes application, benefits, limitations of EBM. It also includes EBM history and background which helps you for examinations. EBM is very important topic in Pharmacotherapeutics-III so you may find this needful.
All the best!!!
Presentation made at the live webinar hosted by the Schizophrenia Research Forum on the 21st of February, 2017 - http://www.schizophreniaforum.org/forums/treatment-resistant-schizophrenia-new-guidelines-diagnosis-and-terminology
John Kane - Treatment-Resistant Schizophrenia: New Guidelines on Diagnosis an...wef
Presentation made at the live webinar hosted by the Schizophrenia Research Forum on the 21st of February, 2017 - http://www.schizophreniaforum.org/forums/treatment-resistant-schizophrenia-new-guidelines-diagnosis-and-terminology
This is a presentation about the importance of Evidence Based Medicine and how it acts as a crucial tool in decision making to empower the quality of medical services for better patient outcomes.
It highlights the steps in EBM process, how to identify the parts of a well built clinical question, resources for literature search, critical appraisal of the evidence, and how to apply the evidence to the patient.
Protective factors against suicidal acts in major depression:Reasons for living, Journal Club Presentation in the Dept of Psychiatric Nursing, Kothamangalam
Progress Monitoring and Therapeutic Alliance in Mental Health TherapyJeremy Weisz
A presentation by Dr. Rylie Moore presented on November 18, 2016 at the OAPA Annual Conference, titled: "Progress monitoring in therapy: On-going assessment of mental health symptoms and the therapeutic alliance".
The presentation addresses how to measure progress in therapy and the importance of the therapeutic alliance.
This topic is very essential for Pharm.D students. It includes application, benefits, limitations of EBM. It also includes EBM history and background which helps you for examinations. EBM is very important topic in Pharmacotherapeutics-III so you may find this needful.
All the best!!!
Presentation made at the live webinar hosted by the Schizophrenia Research Forum on the 21st of February, 2017 - http://www.schizophreniaforum.org/forums/treatment-resistant-schizophrenia-new-guidelines-diagnosis-and-terminology
John Kane - Treatment-Resistant Schizophrenia: New Guidelines on Diagnosis an...wef
Presentation made at the live webinar hosted by the Schizophrenia Research Forum on the 21st of February, 2017 - http://www.schizophreniaforum.org/forums/treatment-resistant-schizophrenia-new-guidelines-diagnosis-and-terminology
This is a presentation about the importance of Evidence Based Medicine and how it acts as a crucial tool in decision making to empower the quality of medical services for better patient outcomes.
It highlights the steps in EBM process, how to identify the parts of a well built clinical question, resources for literature search, critical appraisal of the evidence, and how to apply the evidence to the patient.
Protective factors against suicidal acts in major depression:Reasons for living, Journal Club Presentation in the Dept of Psychiatric Nursing, Kothamangalam
Progress Monitoring and Therapeutic Alliance in Mental Health TherapyJeremy Weisz
A presentation by Dr. Rylie Moore presented on November 18, 2016 at the OAPA Annual Conference, titled: "Progress monitoring in therapy: On-going assessment of mental health symptoms and the therapeutic alliance".
The presentation addresses how to measure progress in therapy and the importance of the therapeutic alliance.
Screening is an essential concept in the field of Medicine, specially in Preventive Medicine. This presentation covers the essentials to understand Screening of Diseases.
Laboratory Medicine Curriculum by
Dr. Belal Aldabbour
When to demand a test (indications)
How to take the sample (and be able to teach the patient on this matter if necessary “e.g. urine sample”)
The rational for ordering tests (which test to order first and why)
The limitations of the test in hand,
The conditions surrounding the findings. (e.g. a moderate yet rapid increase in serum potassium level is
riskier than a higher but slower increase)
Study of the distribution and determinants of
health-related states or events in specified populations and the application of this study to control health problems.
John M. Last, Dictionary of Epidemiology
VALIDITY AND RELIABLITY OF A SCREENING TEST seminar 2.pptxShaliniPattanayak
A presentation shedding some insight into the tricky concepts of validity and reliability of any screening test, used in day-to-day lives, using easy and understandable language.
Biostatistics are widely used in clinical trials to collect and organize and describe and interpret these result and then give to us proves to take appropriate clinical decisions
General principles of research methodology. Terms frequently used in this chapter. It is a course subject for fourth Pharm D in The Tamilnadu Dr.MGR. Medical University, Chennai.
Lecture on causal inference to the pediatric hematology/oncology fellows at Texas Children's hospital as part of their Biostatistics for Busy Clinicians lecture seriers.
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
These lecture slides, by Dr Sidra Arshad, offer a quick overview of the physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar lead (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
6. Describe the flow of current around the heart during the cardiac cycle
7. Discuss the placement and polarity of the leads of electrocardiograph
8. Describe the normal electrocardiograms recorded from the limb leads and explain the physiological basis of the different records that are obtained
9. Define mean electrical vector (axis) of the heart and give the normal range
10. Define the mean QRS vector
11. Describe the axes of leads (hexagonal reference system)
12. Comprehend the vectorial analysis of the normal ECG
13. Determine the mean electrical axis of the ventricular QRS and appreciate the mean axis deviation
14. Explain the concepts of current of injury, J point, and their significance
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. Chapter 3, Cardiology Explained, https://www.ncbi.nlm.nih.gov/books/NBK2214/
7. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
ABDOMINAL TRAUMA in pediatrics part one.drhasanrajab
Abdominal trauma in pediatrics refers to injuries or damage to the abdominal organs in children. It can occur due to various causes such as falls, motor vehicle accidents, sports-related injuries, and physical abuse. Children are more vulnerable to abdominal trauma due to their unique anatomical and physiological characteristics. Signs and symptoms include abdominal pain, tenderness, distension, vomiting, and signs of shock. Diagnosis involves physical examination, imaging studies, and laboratory tests. Management depends on the severity and may involve conservative treatment or surgical intervention. Prevention is crucial in reducing the incidence of abdominal trauma in children.
Integrating Ayurveda into Parkinson’s Management: A Holistic ApproachAyurveda ForAll
Explore the benefits of combining Ayurveda with conventional Parkinson's treatments. Learn how a holistic approach can manage symptoms, enhance well-being, and balance body energies. Discover the steps to safely integrate Ayurvedic practices into your Parkinson’s care plan, including expert guidance on diet, herbal remedies, and lifestyle modifications.
share - Lions, tigers, AI and health misinformation, oh my!.pptxTina Purnat
• Pitfalls and pivots needed to use AI effectively in public health
• Evidence-based strategies to address health misinformation effectively
• Building trust with communities online and offline
• Equipping health professionals to address questions, concerns and health misinformation
• Assessing risk and mitigating harm from adverse health narratives in communities, health workforce and health system
Antimicrobial stewardship to prevent antimicrobial resistanceGovindRankawat1
India is among the nations with the highest burden of bacterial infections.
India is one of the largest consumers of antibiotics worldwide.
India carries one of the largest burdens of drug‑resistant pathogens worldwide.
Highest burden of multidrug‑resistant tuberculosis,
Alarmingly high resistance among Gram‑negative and Gram‑positive bacteria even to newer antimicrobials such as carbapenems.
NDM‑1 ( New Delhi Metallo Beta lactamase 1, an enzyme which inactivates majority of Beta lactam antibiotics including carbapenems) was reported in 2008
Title: Sense of Taste
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the structure and function of taste buds.
Describe the relationship between the taste threshold and taste index of common substances.
Explain the chemical basis and signal transduction of taste perception for each type of primary taste sensation.
Recognize different abnormalities of taste perception and their causes.
Key Topics:
Significance of Taste Sensation:
Differentiation between pleasant and harmful food
Influence on behavior
Selection of food based on metabolic needs
Receptors of Taste:
Taste buds on the tongue
Influence of sense of smell, texture of food, and pain stimulation (e.g., by pepper)
Primary and Secondary Taste Sensations:
Primary taste sensations: Sweet, Sour, Salty, Bitter, Umami
Chemical basis and signal transduction mechanisms for each taste
Taste Threshold and Index:
Taste threshold values for Sweet (sucrose), Salty (NaCl), Sour (HCl), and Bitter (Quinine)
Taste index relationship: Inversely proportional to taste threshold
Taste Blindness:
Inability to taste certain substances, particularly thiourea compounds
Example: Phenylthiocarbamide
Structure and Function of Taste Buds:
Composition: Epithelial cells, Sustentacular/Supporting cells, Taste cells, Basal cells
Features: Taste pores, Taste hairs/microvilli, and Taste nerve fibers
Location of Taste Buds:
Found in papillae of the tongue (Fungiform, Circumvallate, Foliate)
Also present on the palate, tonsillar pillars, epiglottis, and proximal esophagus
Mechanism of Taste Stimulation:
Interaction of taste substances with receptors on microvilli
Signal transduction pathways for Umami, Sweet, Bitter, Sour, and Salty tastes
Taste Sensitivity and Adaptation:
Decrease in sensitivity with age
Rapid adaptation of taste sensation
Role of Saliva in Taste:
Dissolution of tastants to reach receptors
Washing away the stimulus
Taste Preferences and Aversions:
Mechanisms behind taste preference and aversion
Influence of receptors and neural pathways
Impact of Sensory Nerve Damage:
Degeneration of taste buds if the sensory nerve fiber is cut
Abnormalities of Taste Detection:
Conditions: Ageusia, Hypogeusia, Dysgeusia (parageusia)
Causes: Nerve damage, neurological disorders, infections, poor oral hygiene, adverse drug effects, deficiencies, aging, tobacco use, altered neurotransmitter levels
Neurotransmitters and Taste Threshold:
Effects of serotonin (5-HT) and norepinephrine (NE) on taste sensitivity
Supertasters:
25% of the population with heightened sensitivity to taste, especially bitterness
Increased number of fungiform papillae
DISSERTATION on NEW DRUG DISCOVERY AND DEVELOPMENT STAGES OF DRUG DISCOVERYNEHA GUPTA
The process of drug discovery and development is a complex and multi-step endeavor aimed at bringing new pharmaceutical drugs to market. It begins with identifying and validating a biological target, such as a protein, gene, or RNA, that is associated with a disease. This step involves understanding the target's role in the disease and confirming that modulating it can have therapeutic effects. The next stage, hit identification, employs high-throughput screening (HTS) and other methods to find compounds that interact with the target. Computational techniques may also be used to identify potential hits from large compound libraries.
Following hit identification, the hits are optimized to improve their efficacy, selectivity, and pharmacokinetic properties, resulting in lead compounds. These leads undergo further refinement to enhance their potency, reduce toxicity, and improve drug-like characteristics, creating drug candidates suitable for preclinical testing. In the preclinical development phase, drug candidates are tested in vitro (in cell cultures) and in vivo (in animal models) to evaluate their safety, efficacy, pharmacokinetics, and pharmacodynamics. Toxicology studies are conducted to assess potential risks.
Before clinical trials can begin, an Investigational New Drug (IND) application must be submitted to regulatory authorities. This application includes data from preclinical studies and plans for clinical trials. Clinical development involves human trials in three phases: Phase I tests the drug's safety and dosage in a small group of healthy volunteers, Phase II assesses the drug's efficacy and side effects in a larger group of patients with the target disease, and Phase III confirms the drug's efficacy and monitors adverse reactions in a large population, often compared to existing treatments.
After successful clinical trials, a New Drug Application (NDA) is submitted to regulatory authorities for approval, including all data from preclinical and clinical studies, as well as proposed labeling and manufacturing information. Regulatory authorities then review the NDA to ensure the drug is safe, effective, and of high quality, potentially requiring additional studies. Finally, after a drug is approved and marketed, it undergoes post-marketing surveillance, which includes continuous monitoring for long-term safety and effectiveness, pharmacovigilance, and reporting of any adverse effects.
- Video recording of this lecture in English language: https://youtu.be/kqbnxVAZs-0
- Video recording of this lecture in Arabic language: https://youtu.be/SINlygW1Mpc
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
4. Dr. Alaa Hassan - MB BCh, MSc (PH), MD
1. The Common
• Normal is synonymous with “Common" .
• The (95% probability limits) constitute
the most widely accepted normal range.
The normal height of young men is the range of
heights that includes 95% of men.
5. Dr. Alaa Hassan - MB BCh, MSc (PH), MD
2. Not Ill
• Clearly a definition of illness would have to
be devised.
• Illness might thus be defined as anything
that causes
– incapacitation
– pain
– swelling
– bleeding, or
– infection
But is sleep then abnormal?
Would child-birth constitute ill-health?
Is an erection a surgical emergency?
Would menstruation be a sickness?
Is colonic fermentation abnormal?
6. Dr. Alaa Hassan - MB BCh, MSc (PH), MD
3. Operating as Intended
• The muscles are designed to contract
• The bones are designed to support
• What is the intention of axillary hair?
• what the appendix is designed to do?
• what is the purpose of our nails?
7. Dr. Alaa Hassan - MB BCh, MSc (PH), MD
4. Conforming to Cultural Norm
• Acceptable Weight standards may vary
according to culture
• Nose piercing is normal for Hindu
• Nudity is the norm in some African
tribes
8. Dr. Alaa Hassan - MB BCh, MSc (PH), MD
5. The Best
• desirable/optimal/favorable/advantageous
• Maximization of the useful life-span so
that, the degenerative diseases of old age
become the commonest causes of death.
9. Dr. Alaa Hassan - MB BCh, MSc (PH), MD
6. The Therapeutic Definition
• The McMaster Group provide this sixth
definition of normality, which is not used in
conversational English, but which has great
clinical utility.
• Here normality is that range of values (of e.g.
arterial blood pressure, or blood sugar)
where therapy is not indicated (does more
harm than good).
• Patients are therefore not labeled abnormal
unless they are to be treated.
10. Dr. Alaa Hassan - MB BCh, MSc (PH), MD
What’s Exactly Your
Point here?
11. Dr. Alaa Hassan - MB BCh, MSc (PH), MD
If the definition of normality is so
controversial ,
how difficult would it be for a TEST to
distinguish normal from abnormal ?
12. Dr. Alaa Hassan - MB BCh, MSc (PH), MD
Diagnostic Tool
• Any procedure (X-ray, Lab measurement,
questionnaire, Scale etc..) which aims to
differentiate Normal from abnormal.
13. Dr. Alaa Hassan - MB BCh, MSc (PH), MD
Evaluating a Diagnostic Tool
14. Dr. Alaa Hassan - MB BCh, MSc (PH), MD
A diagnostic tool is evaluated in terms
of two distinct features. Namely:
ValidityReliability
(Precision)
15. Dr. Alaa Hassan - MB BCh, MSc (PH), MD
1. Reliability of Diagnostic Tool
• The Percent of agreement or consistency
between multiple observations,
measurements, tests or responses in
regard to the same unit of observation.
• Repeatability
• Giving the same result when applied
several times to the same person.
17. Dr. Alaa Hassan - MB BCh, MSc (PH), MD
Difference between results obtained on the
same person by two or more observers
Inter-observer reliability
Physician 1 Physician 2Same Patient
(Blood Pressure)
140/90 130/80
18. Dr. Alaa Hassan - MB BCh, MSc (PH), MD
Difference between the results obtained by
the same observer on the same person
Intra-observer reliability
6:00 pm 6:00 pm
Same Patient
Same Physician
(Blood Pressure)
140/90 130/80
19. Dr. Alaa Hassan - MB BCh, MSc (PH), MD
Difference between readings of two tests on
the same case or specimen.
Inter-test reliability
Digital Manometer Mercury Manometer
Same Patient
(Blood Pressure)
140/90 130/80
20. Dr. Alaa Hassan - MB BCh, MSc (PH), MD
A special type of inter-observer reliability where there is a
difference between the response of the same individual
to the same question posed by two different interviewers
Respondent Reliability
Interviewer 1 Interviewer 2
(Same Patient )
Sexual Satisfaction
Question
YES NO
21. Dr. Alaa Hassan - MB BCh, MSc (PH), MD
Measurement of reliability
To measure Reliability of blood
Pressure measurement , two
observers were to measure
the systolic blood pressure of
the same 10 patients.
22. Dr. Alaa Hassan - MB BCh, MSc (PH), MD
Subjects Observer 1 Observer 2 Agreement
A 90 90 +
B 90 94 -
C 85 84 -
D 88 88 +
E 92 92 +
F 80 82 -
G 85 85 +
H 98 95 -
I 98 100 -
J 90 90 +
Agreement = 5/10 X100 = 50%
23. Dr. Alaa Hassan - MB BCh, MSc (PH), MD
2. Validity
• This is the accuracy of the test
• The ability of the test to measure what it is
intended to measure.
24. Dr. Alaa Hassan - MB BCh, MSc (PH), MD
Aspects of Diagnostic tool Validity
1. Face Validity
2. Content Validity
3. Construct Validity
4. Criterion
Based Validity
25. Dr. Alaa Hassan - MB BCh, MSc (PH), MD
1. Face Validity
• Not validity in the technical sense
• It refers, not to what the test actually
measures, but to what it appears
superficially to measure.
• Based on intuitive judgement
• The test "looks valid" to the examinees
who take it, the administrative personnel
who decide on its use, and other
technically untrained observers.
Social &
Behavioral
sciences
26. Dr. Alaa Hassan - MB BCh, MSc (PH), MD
2. Content Validity
• Also known as logical validity
• Refers to the extent to which a measure
represents all aspects of a given Disease .
• For example, a depression scale may lack
content validity if it only assesses the
affective aspect of depression but fails to
take into account the behavioral aspect.
Social &
Behavioral
sciences
27. Dr. Alaa Hassan - MB BCh, MSc (PH), MD
3. Construct Validity
• Evaluation of construct validity requires
examining the correlation of the measure being
evaluated with variables that are known to be
related to the construct (Concept) measured by
the instrument being evaluated or for which
there are theoretical grounds for expecting it to
be related (Campbell & Fiske, 1959)
Social &
Behavioral
sciences
28. Dr. Alaa Hassan - MB BCh, MSc (PH), MD
Construct Validity:
A. Convergent Validity
• The scores of a test which evaluates
mathematical skills can be correlated with
scores on other tests that measure basic
mathematical ability,
• High correlations would be evidence of
convergent validity.
Social &
Behavioral
sciences
29. Dr. Alaa Hassan - MB BCh, MSc (PH), MD
Construct Validity:
B. Discriminant Validity
• To show the discriminant validity of a test
of math skills, we might correlate the
scores of our test with scores on tests of
verbal ability, where low correlations would
be evidence of discriminant validity.
Social &
Behavioral
sciences
30. Dr. Alaa Hassan - MB BCh, MSc (PH), MD
4. Criterion Based Validity
• A defined population is subjected to
– The test under investigation and
– A standard test (Gold Standard)
• The gold standard will determine
– Those who are diseased and
– Those who are disease free
• The performance of the new test is
compared to the Classification of the gold
standard test
31. Dr. Alaa Hassan - MB BCh, MSc (PH), MD
Criterion
Based
Validity
Sensitivity
Specificity
Positive Predictive value
Negative Predictive value
32. Dr. Alaa Hassan - MB BCh, MSc (PH), MD
Positive Likelihood Ratios
• likelihood ratios are not yet commonly
reported in peer-reviewed literature or in
marketing information provided by test
manufacturers.
• They can be a valuable tool for comparing
the accuracy of several tests to the gold
standard, and
• They are NOT dependent upon the
prevalence of disease.
33. Dr. Alaa Hassan - MB BCh, MSc (PH), MD
The positive LR represents :
the odds of a positive test in an infected population
compared to
the odds of a positive test a non infected population.
TP/ All Diseased
————--------—
FP/ All Disease free
Or it can also be expressed as :
sensitivity
—————
1-specificity
34. Dr. Alaa Hassan - MB BCh, MSc (PH), MD
Diseased
Not
Diseased
Test
Positive
TP+FP
(All Test Positive)
Test
Negative
TN+FN
(All Test Negative)
TP+FN
(All Diseased)
TN+FP
(All Disease Free)
TP
TN
FP
FN
Positive Likelihood Ratio
35. Dr. Alaa Hassan - MB BCh, MSc (PH), MD
• Useful tests have larger positive LR
• Less useful tests will have smaller positive
LR.
36. Dr. Alaa Hassan - MB BCh, MSc (PH), MD
Example:
A test with a positive LR of 5.0 :
– For every
• 1 non-infected subjects that test positive
• 5 of the infected subjects will test positive.
– For every
• 1 false positive
• 5 true positives
– True positives are 5 times False Positives
37. Dr. Alaa Hassan - MB BCh, MSc (PH), MD
The Negative LR represents :
the odds of a Negative test in an infected population
compared to
the odds of a Negative test in a non infected population.
FN/ All Diseased
------------—————
TN/ All Disease free
Or it can also be expressed as :
1- Sensitivity
—----------------——
Specificity
38. Dr. Alaa Hassan - MB BCh, MSc (PH), MD
Diseased
Not
Diseased
Test
Positive
TP+FP
(All Test Positive)
Test
Negative
TN+FN
(All Test Negative)
TP+FN
(All Diseased)
TN+FP
(All Disease Free)
TP
TN
FP
FN
Negative Likelihood Ratio
39. Dr. Alaa Hassan - MB BCh, MSc (PH), MD
• Useful tests have negative LR close to 0
• Less useful tests have higher negative LR.